HIV-1 抗体：感染与疫苗接种的启示，有助于指导疫苗设计。
HIV-1 antibodies from infection and vaccination: insights for guiding vaccine design.
机构信息
Duke Human Vaccine Institute, Duke University Medical Center, Durham, NC 27710, USA.
出版信息
Trends Microbiol. 2012 Nov;20(11):532-9. doi: 10.1016/j.tim.2012.08.011. Epub 2012 Sep 13.
Abstract
Attempts to formulate a protective HIV-1 vaccine through classic vaccine design strategies have not been successful. Elicitation of HIV-1-specific broadly neutralizing antibodies (bnAbs) at high titers that are present before exposure might be required to achieve protection. Recently, the application of new technologies has facilitated the study of clonal lineages of HIV-1 envelope (Env) antibodies, which have provided insights into HIV-1 antibody development during infection and upon vaccination. Strategies are being developed for the analysis of infection and vaccine candidate-induced antibodies, their gene usage, and their maturation pathways such that this information can be used to attempt to guide rational vaccine design.
摘要
通过经典疫苗设计策略来尝试制定一种保护性 HIV-1 疫苗尚未成功。在接触前可能需要诱导出高滴度的 HIV-1 特异性广泛中和抗体（bnAbs）才能实现保护。最近，新技术的应用促进了 HIV-1 包膜 (Env) 抗体克隆谱系的研究，这些研究提供了对感染和接种疫苗期间 HIV-1 抗体发育的深入了解。目前正在制定分析感染和候选疫苗诱导的抗体、它们的基因使用以及它们的成熟途径的策略，以便利用这些信息尝试指导合理的疫苗设计。
相似文献
1
HIV-1 antibodies from infection and vaccination: insights for guiding vaccine design.HIV-1 抗体：感染与疫苗接种的启示，有助于指导疫苗设计。
Trends Microbiol. 2012 Nov;20(11):532-9. doi: 10.1016/j.tim.2012.08.011. Epub 2012 Sep 13.
2
A Trimeric HIV-1 Envelope gp120 Immunogen Induces Potent and Broad Anti-V1V2 Loop Antibodies against HIV-1 in Rabbits and Rhesus Macaques.一种三聚体HIV-1包膜糖蛋白120免疫原在兔和恒河猴中诱导出针对HIV-1的强效且广谱的抗V1V2环抗体。
J Virol. 2018 Feb 12;92(5). doi: 10.1128/JVI.01796-17. Print 2018 Mar 1.
3
HIV-1 envelope glycoprotein immunogens to induce broadly neutralizing antibodies.HIV-1 包膜糖蛋白免疫原诱导广泛中和抗体。
Expert Rev Vaccines. 2016;15(3):349-65. doi: 10.1586/14760584.2016.1129905. Epub 2016 Jan 8.
4
Rational antibody-based HIV-1 vaccine design: current approaches and future directions.基于理性抗体的 HIV-1 疫苗设计：当前方法和未来方向。
Curr Opin Immunol. 2010 Jun;22(3):358-66. doi: 10.1016/j.coi.2010.02.012. Epub 2010 Mar 17.
5
Natural infection as a blueprint for rational HIV vaccine design.作为合理设计HIV疫苗蓝本的自然感染
Hum Vaccin Immunother. 2017 Jan 2;13(1):229-236. doi: 10.1080/21645515.2016.1232785. Epub 2016 Sep 20.
6
Rapid Induction of Multifunctional Antibodies in Rabbits and Macaques by Clade C HIV-1 CAP257 Envelopes Circulating During Epitope-Specific Neutralization Breadth Development.通过在表位特异性中和广度发展过程中循环的 C 群 HIV-1 CAP257 包膜，快速诱导兔和猕猴产生多功能抗体。
Front Immunol. 2020 Jun 2;11:984. doi: 10.3389/fimmu.2020.00984. eCollection 2020.
7
Rational design of vaccines to elicit broadly neutralizing antibodies to HIV-1.设计引发 HIV-1 广谱中和抗体的疫苗的合理性。
Cold Spring Harb Perspect Med. 2011 Sep;1(1):a007278. doi: 10.1101/cshperspect.a007278.
8
Strategies for eliciting multiple lineages of broadly neutralizing antibodies to HIV by vaccination.通过接种疫苗诱导 HIV 广泛中和抗体的多种谱系的策略。
Curr Opin Virol. 2021 Dec;51:172-178. doi: 10.1016/j.coviro.2021.09.015. Epub 2021 Nov 4.
9
Broadly Neutralizing Antibodies Against HIV: New Insights to Inform Vaccine Design.广谱中和抗体抗 HIV：为疫苗设计提供新的见解。
Annu Rev Med. 2016;67:185-200. doi: 10.1146/annurev-med-091014-090749. Epub 2015 Nov 9.
10
Broadly neutralizing antibodies: What is needed to move from a rare event in HIV-1 infection to vaccine efficacy?广谱中和抗体：从 HIV-1 感染中的罕见事件到疫苗效力，还需要什么？
Retrovirology. 2018 Jul 28;15(1):52. doi: 10.1186/s12977-018-0433-2.
引用本文的文献
1
Transient regulatory T cell manipulation is limited by anti-antibody responses in HIV-1 envelope immunized rhesus macaques.在经HIV-1包膜免疫的恒河猴中，短暂性调节性T细胞的操控受到抗抗体反应的限制。
iScience. 2025 Jul 23;28(8):113191. doi: 10.1016/j.isci.2025.113191. eCollection 2025 Aug 15.
2
Autoreactivity and broad neutralization of antibodies against HIV-1 are governed by distinct mutations: Implications for vaccine design strategies.抗体对 HIV-1 的自身反应性和广泛中和作用受不同突变的控制：对疫苗设计策略的影响。
Front Immunol. 2022 Nov 18;13:977630. doi: 10.3389/fimmu.2022.977630. eCollection 2022.
3
Vaccine Design Informed by Virus-Induced Immunity.基于病毒诱导免疫的疫苗设计。
Viral Immunol. 2020 May;33(4):342-350. doi: 10.1089/vim.2019.0138. Epub 2020 May 5.
4
Update on Fc-Mediated Antibody Functions Against HIV-1 Beyond Neutralization.HIV-1 中和作用以外的 Fc 介导的抗体功能更新。
Front Immunol. 2019 Dec 18;10:2968. doi: 10.3389/fimmu.2019.02968. eCollection 2019.
5
Novel vaccines: Technology and development.新型疫苗：技术与开发。
J Allergy Clin Immunol. 2019 Mar;143(3):844-851. doi: 10.1016/j.jaci.2018.05.021. Epub 2018 Jun 30.
6
Multi-Envelope HIV-1 Vaccine Development: Two Targeted Immune Pathways, One Desired Protective Outcome.多包膜HIV-1疫苗研发：两条靶向免疫途径，一个预期的保护结果。
Viral Immunol. 2018 Mar;31(2):124-132. doi: 10.1089/vim.2017.0144. Epub 2018 Jan 9.
7
Humoral and Innate Antiviral Immunity as Tools to Clear Persistent HIV Infection.体液免疫和天然抗病毒免疫作为清除持续性HIV感染的工具
J Infect Dis. 2017 Mar 15;215(suppl_3):S152-S159. doi: 10.1093/infdis/jiw555.
8
A heterologous prime-boosting strategy with replicating Vaccinia virus vectors and plant-produced HIV-1 Gag/dgp41 virus-like particles.一种采用复制型痘苗病毒载体和植物生产的HIV-1 Gag/dgp41病毒样颗粒的异源初免-加强免疫策略。
Virology. 2017 Jul;507:242-256. doi: 10.1016/j.virol.2017.04.008. Epub 2017 Apr 28.
9
Stabilized HIV-1 envelope glycoprotein trimers for vaccine use.用于疫苗的稳定化HIV-1包膜糖蛋白三聚体。
Curr Opin HIV AIDS. 2017 May;12(3):241-249. doi: 10.1097/COH.0000000000000363.
10
Humanized Immunoglobulin Mice: Models for HIV Vaccine Testing and Studying the Broadly Neutralizing Antibody Problem.人源化免疫球蛋白小鼠：用于HIV疫苗测试和研究广泛中和抗体问题的模型。
Adv Immunol. 2017;134:235-352. doi: 10.1016/bs.ai.2017.01.004.
本文引用的文献
1
Antibody-dependent cellular cytotoxicity-mediating antibodies from an HIV-1 vaccine efficacy trial target multiple epitopes and preferentially use the VH1 gene family.抗体依赖的细胞毒性介导的抗体来自 HIV-1 疫苗功效试验，靶向多个表位，并且优先使用 VH1 基因家族。
J Virol. 2012 Nov;86(21):11521-32. doi: 10.1128/JVI.01023-12. Epub 2012 Aug 15.
2
Magnitude and breadth of the neutralizing antibody response in the RV144 and Vax003 HIV-1 vaccine efficacy trials.RV144 和 Vax003 HIV-1 疫苗功效试验中的中和抗体反应的幅度和广度。
J Infect Dis. 2012 Aug 1;206(3):431-41. doi: 10.1093/infdis/jis367. Epub 2012 May 25.
3
Isolation of HIV-1-neutralizing mucosal monoclonal antibodies from human colostrum.从人初乳中分离 HIV-1 中和黏膜单克隆抗体。
PLoS One. 2012;7(5):e37648. doi: 10.1371/journal.pone.0037648. Epub 2012 May 18.
4
B-cell-lineage immunogen design in vaccine development with HIV-1 as a case study.以 HIV-1 为例的疫苗开发中的 B 细胞系免疫原设计。
Nat Biotechnol. 2012 May 7;30(5):423-33. doi: 10.1038/nbt.2197.
5
BLyS-mediated modulation of naive B cell subsets impacts HIV Env-induced antibody responses.BLyS 介导的幼稚 B 细胞亚群的调节影响 HIV Env 诱导的抗体反应。
J Immunol. 2012 Jun 15;188(12):6018-26. doi: 10.4049/jimmunol.1200466. Epub 2012 May 4.
6
HIV-1 gp120 vaccine induces affinity maturation in both new and persistent antibody clonal lineages.HIV-1 gp120 疫苗诱导新的和持续的抗体克隆谱系的亲和力成熟。
J Virol. 2012 Jul;86(14):7496-507. doi: 10.1128/JVI.00426-12. Epub 2012 May 2.
7
Immune-correlates analysis of an HIV-1 vaccine efficacy trial.HIV-1 疫苗功效试验的免疫相关性分析。
N Engl J Med. 2012 Apr 5;366(14):1275-86. doi: 10.1056/NEJMoa1113425.
8
HIV-1 antiretroviral drug therapy.HIV-1 抗逆转录病毒药物治疗。
Cold Spring Harb Perspect Med. 2012 Apr;2(4):a007161. doi: 10.1101/cshperspect.a007161.
9
Selection pressure on HIV-1 envelope by broadly neutralizing antibodies to the conserved CD4-binding site.广谱中和抗体对 HIV-1 包膜的选择压力作用于保守的 CD4 结合位点。
J Virol. 2012 May;86(10):5844-56. doi: 10.1128/JVI.07139-11. Epub 2012 Mar 14.
10
PGV04, an HIV-1 gp120 CD4 binding site antibody, is broad and potent in neutralization but does not induce conformational changes characteristic of CD4.PGV04 是一种 HIV-1 gp120 CD4 结合位点抗体，具有广谱和高效的中和作用，但不会诱导 CD4 特征性的构象变化。
J Virol. 2012 Apr;86(8):4394-403. doi: 10.1128/JVI.06973-11. Epub 2012 Feb 15.
Zotero 插件